详情页 - 首都医科大学宣武医院知识库

资源类型：

文章类型：

作者：

Yang Yang[1] * ; He Yingjian[1] ; Fan Zhaoqing[2] ; Chen Xue[1] ; Liu Yiqiang[1] ; Zhang Chao[3] ; Jiang Hongchuan[3] ; Wang Xin[4] ; Wang Xiang[4] ; Xie Fei[5] ; Wang Shu[5] ; Luo Bin[6] ; Kang Hua[7]

; Wang Tao[8] ; Jiang Zefei[8] ; Yuan Peng[4] ; Xu Binhe[4] ; Xu Ling[9] ; Liu Yinhua[9] ; Li Jinfeng[1] ; Xie Yuntao[1] ; Wang Tianfeng[1] ; Ouyang Tao[1] ;

机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China. [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China. zhqfan@bjmu.edu.cn. [3]Beijing Chao Yang Hospital, Breast Disease Department, Beijing, China. [4]Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China. [5]Peking University People's Hospital, Breast Cancer Center, Beijing, China. [6]Beijing Tsinghua Changgeng Hospital, Breast Disease Department, Beijing, China. [7]Xuan Wu Hospital Capital Medical University, Breast Disease Department, Beijing, China. [8]307 Hospital of PLA, Breast Cancer Department, Beijing, China. [9]Peking University First Hospital, Breast Cancer Center, Beijing, China.

出处：

DOI：

ISSN：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区肿瘤学

第一作者：

第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial

文献详情